Bioavailability intelligence, grounded in PK

See which formulations get more of the compound into the body.

Availabio helps supplement brands compare formulation options, interaction assumptions, and evidence strength before the next R&D or commercial decision. Individuals can create a free account to explore timing, interaction context, and wearable-informed signals.

PK outputs are model-derived estimates for educational and formulation intelligence use only. Not clinical or legal advice.

Also using Availabio for yourself? Start free to explore supplement timing, interaction context, and wearable-informed signals.

529
CYP pathwaysmetabolic route coverage
28
curated compoundssource-verified parameters
IVIVE
IVIVE-informed PK simulationextrapolation method
A/B/C/D
evidence gradesper parameter, every output

What your team would actually use this for

A formulation team comparing two curcumin formats can use Availabio to frame expected PK differences, interaction assumptions, evidence grade, and source confidence before committing to deeper validation work.
Formulation intelligence scenario

Compare formulation options

Evaluate how different delivery formats affect expected bioavailability under similar dosing conditions, using IVIVE-informed PK estimates.

Check interaction assumptions

Surface relevant CYP pathway interactions and enzyme competition scenarios before writing your formulation rationale or product brief.

Review evidence strength

Every parameter carries an A/B/C/D evidence grade so your team can distinguish a well-supported estimate from an early-stage hypothesis.

Why evidence grades matter

Not every compound parameter is equally strong. Availabio shows whether a result comes from in vivo human data, weaker preclinical evidence, or model-derived inference — so teams can tell the difference between a stronger formulation brief and an early hypothesis.

A

In vivo human data

Supported by published human clinical or pharmacokinetic studies. Stronger basis for formulation planning and R&D review.

B

In vivo animal / ex vivo

Supported by animal PK studies or validated ex vivo data. Useful directionally; interpretation requires additional context.

C

In vitro / model-derived

Derived from cell or enzyme assays, or PK model inference. Useful for framing early hypotheses; weaker confidence in isolation.

D

Structural / predicted

Inferred from molecular structure or QSAR prediction. Exploratory context only; should not drive standalone product claims.

Decision framing: Stronger grades (A, B) support formulation planning and R&D review. Weaker grades (C, D) remain early hypothesis or context. Availabio makes this distinction explicit so teams avoid overclaiming on limited evidence.

Two paths, one intelligence layer

For Brands

Formulation intelligence for product and R&D teams

Compare formulation assumptions, ingredient interaction scenarios, and evidence strength before the next R&D or commercial decision. Includes API access, team workspaces, and jurisdiction-aware context.

Request Brand Demo View Pricing
For Individuals

Personal supplement intelligence

Use Availabio personally to explore your supplement stack, timing, and wearable-informed context with a free account.

Create Free Account Connect Wearable

Transparent tier pricing

Exact public pricing. Full details and feature breakdown on the pricing page.

Brand Intelligence Pro

$1,199/month

Enterprise

from $3,000/month
View Full Pricing & Features

Request a brand walkthrough

Tell us your use case and we will tailor the most relevant walkthrough for your team.

What to expect

Demo requests are captured directly in our platform for follow-up. Best for nutraceutical R&D, formulation science, product, and technical teams evaluating formulation intelligence and API integration.

You can also review API endpoints immediately via /api-docs.

Educational and formulation intelligence use only. PK simulation outputs are model-derived estimates informed by IVIVE methodology. Availabio includes jurisdiction-aware compound notes where available across US, EU, and Colombia. Outputs are not clinical advice, not legal advice, and not intended for regulatory submission.